Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is highlighted as a promising healthcare stock with significant upside potential, particularly following Goldman Sachs' initiation of coverage with a Buy rating and a price target of $125 [1]. Group 1: Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, specifically targeting neurobehavioral and metabolic disorders [3]. - The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR), is an oral tablet designed to treat Prader-Willi Syndrome (PWS) [3]. Group 2: Recent Developments - Goldman Sachs anticipates that Soleno Therapeutics' Vykat XR will become a foundational treatment for Prader-Willi syndrome, with expectations for the drug to evolve into a blockbuster franchise [2]. - The recent pullback in the stock price is viewed as an attractive entry point for investors looking to capitalize on the company's potential [2].

Core Insights - Soleno Therapeutics has appointed Mark W. Hahn as an independent director to its Board of Directors, enhancing the board's expertise with nearly 30 years of CFO-level experience in the biopharmaceutical sector [1][2] - The addition of Mr. Hahn brings the total number of board members to seven, which is expected to support the company's ongoing commercial launch of VYKAT™ XR [1][2] Company Overview - Soleno Therapeutics is focused on developing novel therapeutics for rare diseases, with its first commercial product, VYKAT™ XR, approved by the FDA on March 26, 2025 [11] - VYKAT™ XR is indicated for treating hyperphagia in patients aged 4 years and older with Prader-Willi syndrome (PWS) [6][11] Leadership and Experience - Mark W. Hahn has a strong background in financial leadership, having served as CFO for several companies, including Verona Pharma PLC and Dova Pharmaceuticals, where he played key roles in product launches and capital raising [2][3] - His experience includes overseeing Verona Pharma's phase 3 program and its acquisition by Merck & Co., Inc. for approximately $10 billion [2] Product Information - VYKAT™ XR is designed to address hyperphagia, a severe condition associated with PWS, which can significantly impact the quality of life for affected individuals [5][6] - The product is now commercially available to U.S. patients following its FDA approval [6][11]

Core Insights - Soleno Therapeutics has experienced a significant decline of approximately 24% since the previous article's rating of "Hold" following the approval enthusiasm for VYKAT [1] Group 1 - The article reflects on the author's investment philosophy, emphasizing that both failures and successes in investing serve as valuable learning experiences [1] - The author has focused research on healthcare stocks for about five years, indicating a specialized knowledge in this sector [1] Group 2 - The author expresses appreciation for reader engagement and shared experiences, highlighting the community aspect of investment discussions [1]

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. for possible violations of federal securities laws and unlawful business practices affecting stockholders [1][2]. Investigation Details - The law firm is reaching out to investors who purchased or acquired Soleno shares and suffered losses, encouraging them to discuss their legal rights [1][2]. - There is no cost or obligation for investors to contact the firm regarding these claims [2]. Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3]. Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5].

Core Insights - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as a promising biotech stock with significant potential, supported by a Buy rating and a price target of $145.00 from Piper Sandler [1] Financial Performance - In fiscal Q2 2025, Soleno Therapeutics reported a cash usage of $12.6 million in operating activities for the three months ending June 30, 2025 [2] - The company had $293.8 million in cash, cash equivalents, and marketable securities at the end of Q2 2025, excluding $230 million raised from a common stock offering in July [2] Revenue Generation - The net product revenue for Soleno Therapeutics in the reported quarter reached $32.7 million [3] - The company is focused on developing therapeutics for rare diseases, particularly neurobehavioral and metabolic disorders, with its lead candidate being Diazoxide Choline Controlled-Release (DCCR) for Prader-Willi Syndrome [3]

Core Insights - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is recognized as a strong buy stock by Wall Street, with Wells Fargo analyst Derek Archila reiterating a Buy rating and setting a price target of $123.00 [1] Financial Performance - For the three months ended June 30, 2025, Soleno Therapeutics reported a cash usage of $12.6 million in its operating activities [2] - As of the end of the second quarter, the company had $293.8 million in cash, cash equivalents, and marketable securities [2] - The cash balance at the end of Q2 does not include $230 million raised through an underwritten offering of common stock in July [3] - Product revenue for the quarter reached $32.7 million [3] Company Overview - Soleno Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for rare diseases, particularly neurobehavioral and metabolic disorders [4] - The company's lead candidate is Diazoxide Choline Controlled-Release (DCCR), an oral tablet designed to treat Prader-Willi Syndrome (PWS) [4]

Core Insights - Bragar Eagel & Squire, P.C. is investigating potential claims against Soleno Therapeutics, Inc. regarding possible violations of federal securities laws and unlawful business practices [1][2] Investigation Details - The law firm is reaching out to Soleno stockholders who have suffered losses, encouraging them to discuss their legal rights and options [1][2] - There is no cost or obligation for stockholders to inquire about their rights or the ongoing investigation [2] Company Background - Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, South Carolina, and California, representing individual and institutional investors in various complex litigations [3] Recent Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's product, Vykat XR, as overpriced and potentially unsafe for children, leading to a significant drop in Soleno's stock price by $5.73 per share, or 7.41%, closing at $71.63 [5]

Core Insights - Acadia Pharmaceuticals' experimental drug carbetocin failed in Phase 3 testing for treating excessive hunger in patients with Prader-Willi syndrome, leading to a nearly 12% drop in its stock price [2][3][4] - The company has decided to halt further development of carbetocin, as it did not show statistically significant improvement compared to the placebo group [4] - Despite the setback, Acadia is positioned for long-term growth with two approved products expected to generate $1 billion in net sales this year and a pipeline of eight disclosed and multiple undisclosed programs [5][6] Company Performance - Acadia Pharmaceuticals' stock fell to approximately $20.80, marking an 11-week low following the news of the drug failure [3] - RBC Capital Markets analyst Brian Abrahams suggested that the stock's decline presents a buying opportunity, maintaining an outperform rating with a price target of $40 [6] Competitive Landscape - The failure of Acadia's drug has positively impacted Soleno Therapeutics, which is also developing a treatment for Prader-Willi syndrome, resulting in a 13.4% increase in its stock price to $64.49 [3][6] - Soleno Therapeutics has received a Relative Strength Rating upgrade, indicating improving technical performance [7][8]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Soleno Therapeutics, Inc. following a negative report on its product Vykat XR, which led to a significant drop in the company's stock price [1][3]. Group 1: Investigation Details - Pomerantz LLP is representing investors of Soleno Therapeutics, Inc. and is looking into claims of securities fraud or other unlawful practices by the company and its officers [1]. - The investigation was prompted by a report from Scorpion Capital that criticized Soleno's only product, Vykat XR, labeling it as overpriced and potentially unsafe for children [3]. Group 2: Stock Price Impact - Following the release of the Scorpion report on August 15, 2025, Soleno's stock price decreased by $5.73 per share, which is a decline of 7.41%, closing at $71.63 per share on the same day [3]. Group 3: Company Background - Soleno Therapeutics, Inc. is a company that has been under scrutiny due to concerns regarding its product and business practices, which may affect investor confidence and market performance [1][3].

Core Insights - Soleno Therapeutics, Inc. is identified as one of the most oversold healthcare stocks in 2025, primarily due to stock volatility following the launch of its FDA-approved product, VYKAT XR, for treating hyperphagia in Prader-Willi Syndrome [2][4] Company Overview - Soleno Therapeutics, Inc. is a clinical-stage biotech company focused on rare diseases, with VYKAT XR being its lead product [2] - The company is pursuing European approval through the EMA, indicating a strategy for international market expansion [3][5] Market Performance - The stock experienced a significant decline of over 10% in mid-August due to a short-seller report raising safety concerns about VYKAT XR, leading to a securities class action investigation [3] - Despite the decline, VYKAT XR has initiated treatment for 646 patients from 295 prescribers, covering over 100 million U.S. lives [3] - The stock has lost approximately 26% in a month, but technical indicators suggest that selling pressure may be nearing exhaustion [4] Analyst Sentiment - Analysts maintain optimistic buy ratings for Soleno Therapeutics, with average price targets ranging from $110 to $120, reflecting confidence in the company's long-term commercial potential [4]